Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity

Inclusion Criteria:

1. Aged ≥ 18 years old at the time of verbal consent to participate in the study.

2. Initiating brodalumab as part of routine clinical care through the SILIQ (brodalumab) Patient Support Program (PSP) for the treatment of plaque psoriasis buthas not yet received their first dose. Decision to treat with brodalumab must havebeen reached prior to and independently of recruitment in the study.

3. Must be able to read, understand, and communicate in English or French.

4. Willing and able to provide informed consent on an online platform using anIndependent Ethics Committee (IEC) or Institutional Review Board (IRB) approvedelectronic Informed Consent Form (ICF) in English or French.

Exclusion Criteria:

1. Not willing or able to complete ePROs (electronic Patient Reported Outcomes) on anonline platform (using a computer or mobile device).

2. Participation in brodalumab phase IV study (NCT04149587).

3. Participation in an interventional clinical trial concurrently or within the last 30days prior to providing verbal consent to participate in this study.

4. Patient with Crohn's disease or with clinically significant hypersensitivity tobrodalumab or to any of the excipients or component of the container (contraindications as per the Product Monograph).

5. Presence of any other serious and/or uncontrolled medical condition that, in theopinion of the investigator, prohibits the patient from participating in the study.